RESEARCH PAPER

Granisetron in the Management of Chemotherapy-Induced Nausea and Vomiting: Emerging Trends in Antiemetic Therapy

Dr. Shital J. Bidkar[1*], Ms. Pooja G. Pate[1], Ms. Ashlesha G. Pate[1], Ms. Anushka N. Patil[1], Ms. Sakshi M. Paliwal[1], Ms. Rumani M. Bhoir[1], Ms. Chitra B. Dive[1], Dr. Kiran C. Mahajan[1], Dr. Ganesh Y. Dama[2]

[1]Department of Pharmaceutics, Sgmspm'S Sharadchandra Pawar College of Pharmacy, Dumberwadi (Otur), Tal. Junnar, Dist. Pune, Maharashtra, India, 410504

[2]Department of Pharmacognosy, Sgmspm'S Sharadchandra Pawar College of Pharmacy, Dumberwadi (Otur), Tal. Junnar, Dist. Pune, Maharashtra, India, 410504

[*]Corresponding Author: Dr. Shital J. Bidkar, Department of Pharmaceutics, Sgmspm'S Sharadchandra Pawar College of Pharmacy, Dumberwadi (Otur), Tal. Junnar, Dist. Pune, Maharashtra, India, 410504

Email: shitalbidkar@yahoo.com

Received: 17th Mar, 2026 | Revised: 29th Mar, 2026 | Accepted: 19th Apr, 2026 | Available Online: 5th May, 2026

ABSTRACT

Chemotherapy-induced nausea and vomiting (CINV) is one of the most debilitating adverse effects associated with cancer chemotherapy, significantly affecting patient compliance and quality of life . Despite advances in antiemetic therapy, optimal control of CINV remains a challenge, particularly in highly emetogenic chemotherapy regimens Granisetron, a selective 5-HT3 receptor antagonist, plays a crucial role in the prevention and management of CINV due to its high efficacy and favourable safety profile. Recent innovations in drug delivery systems, including transdermal patches, buccal films, and nanotechnology-based carriers, have further enhanced its therapeutic performance. This review critically evaluates the pathophysiology of CINV, pharmacological profile of granisetron, and recent advances in drug delivery systems aimed at improving antiemetic therapy.

Keywords: Granisetron; Cinv; 5-Ht3 Receptor Antagonists; Drug Delivery Systems; Nanotechnology; Transdermal

How to cite this article: Bidkar S J, Pate P G, Pate A G, Patil A N, Paliwal S M, Bhoir R M, Dive C B, Mahajan K C, Dama G Y., Granisetron in the Management of Chemotherapy-Induced Nausea and Vomiting: Emerging Trends in Antiemetic Therapy. Int J Drug Deliv Technol. 2026;16(44s): 81-88; Doi: 10.25258/Ijddt.16.44s.12

INTRODUCTION

Chemotherapy-induced nausea and vomiting (CINV) remain one of the most common and distressing adverse effects associated with cancer chemotherapy, significantly impairing patient quality of life and treatment adherence. Despite major advancements in oncology therapeutics, CINV continues to occur in approximately 30–80% of patients depending on the emetogenic potential of chemotherapeutic agents and individual patient susceptibility. This adverse effect is clinically significant as it may lead to dose reduction, treatment delay, or even discontinuation of potentially life-saving chemotherapy regimens.The pathophysiology of CINV is complex and involves both central and peripheral mechanisms. Chemotherapeutic agents stimulate enterochromaffin cells in the gastrointestinal tract to release serotonin (5-hydroxytryptamine, 5-HT), which subsequently activates 5-HT3 receptors on vagal afferent neurons, transmitting emetic signals to the chemoreceptor trigger zone (CTZ) and vomiting center in the medulla oblongata. In addition to serotonin-mediated pathways, substance P and neurokinin-1 (NK1) receptors play a significant role, particularly in delayed-phase CINV.[1-5] This multifactorial mechanism highlights the need for targeted and multimodal antiemetic therapy.

The introduction of serotonin (5-HT3) receptor antagonists has revolutionized the management of CINV. Among these agents, granisetron is a highly selective and potent 5-HT3 receptor antagonist widely used in clinical oncology practice . It exhibits strong receptor binding affinity, improved pharmacokinetic stability, and a relatively longer duration of action compared to first-generation antiemetics such as metoclopramide and chlorpromazine. Granisetron has demonstrated significant efficacy in preventing both acute and delayed phases of CINV when used alone or in combination with corticosteroids and NK1 receptor antagonists.Although conventional formulations of granisetron such as oral tablets and intravenous injections are clinically effective, they are associated with certain limitations including

short half-life, requirement of repeated dosing, and reduced patient compliance during vomiting episodes. Additionally, oral administration may be compromised in patients experiencing severe nausea, leading to reduced therapeutic effectiveness .[6-10]To overcome these limitations, significant research efforts have been directed toward the development of novel drug delivery systems. Advanced formulations such as transdermal patches, orally disintegrating tablets, buccal films, and controlled-release injectable systems have been explored to improve bioavailability, prolong drug release, and enhance patient convenience. These innovative delivery approaches not only improve pharmacokinetic performance but also ensure sustained antiemetic coverage during both acute and delayed phases of chemotherapy-induced emesis Furthermore, emerging technologies including nanotechnology-based drug delivery systems have opened new avenues for optimizing granisetron therapy. Nanocarriers such as liposomes, polymeric nanoparticles, and solid lipid nanoparticles have shown potential in enhancing drug solubility, stability, and targeted delivery while minimizing systemic side effects. Such advancements are aligned with the principles of Quality by Design (QbD), which emphasize systematic formulation development and robust product performance. In addition, patient-centric drug delivery systems are gaining importance in modern pharmaceutics. The development of non-invasive and self-administered dosage forms is particularly beneficial in oncology patients, where ease of administration and rapid onset of action are critical. Granisetron-based innovations therefore represent a significant step toward improving therapeutic outcomes and patient quality of life in cancer chemotherapy. Overall, despite the availability of multiple antiemetic therapies, CINV continues to remain a clinical challenge. Continuous advancements in pharmacology and drug delivery systems are essential to achieve optimal control of emesis in cancer patients. This review critically evaluates the pharmacological profile of granisetron, its clinical role, and recent innovations in drug delivery systems aimed at improving therapeutic efficacy in CINV management [10-16]

Pathophysiology of Chemotherapy-Induced Nausea and Vomiting (CINV)

The pathophysiology of chemotherapy-induced nausea and vomiting (CINV) involves complex interactions between the peripheral gastrointestinal system and central nervous system pathways, resulting in activation of the emetic reflex. Cytotoxic chemotherapy agents induce damage to enterochromaffin cells lining the gastrointestinal mucosa, leading to the rapid release of serotonin (5-hydroxytryptamine, 5-HT), which plays a central role in initiating emesis. This released serotonin binds to 5-HT3 receptors located on vagal afferent neurons, transmitting signals to the chemoreceptor trigger zone (CTZ) and the vomiting center in the medulla oblongata.[4,5,6] CINV is clinically classified into four major types based on the onset and underlying mechanisms: acute, delayed, anticipatory, and breakthrough nausea and vomiting . Acute CINV typically occurs within the first 24 hours following chemotherapy administration and is predominantly mediated by serotonin release and 5-HT3 receptor activation . In contrast, delayed CINV occurs after 24 hours and may persist for several days, with substance P acting on neurokinin-1 (NK1) receptors playing a dominant role in its pathogenesis . Anticipatory CINV is considered a conditioned psychological response that develops due to previous negative chemotherapy experiences, whereas breakthrough CINV occurs despite prophylactic antiemetic therapy and often requires rescue medication .The involvement of multiple neurotransmitters, including serotonin, dopamine, and substance P, highlights the multifactorial nature of CINV and underscores the need or combination antiemetic therapy targeting different receptor pathways . Clinical guidelines such as those developed by MASCC and ESMO recommend the use of 5-HT3 receptor antagonists, corticosteroids, and NK1 receptor antagonists in combination to achieve optimal control of both acute and delayed CINV.[1,11]

Furthermore, recent research has emphasized the role of central nervous system integration in modulating emetic responses, where signals from the gastrointestinal tract are processed along with inputs from higher cortical centers, contributing to variability in patient response. This complexity necessitates the development of individualized treatment strategies and advanced drug delivery systems to improve therapeutic outcomes.[14.15]

Pharmacological Characteristics of Granisetron

Granisetron plays a crucial role in the initiation of chemotherapy-induced emesis. By competitively inhibiting 5-HT3 receptors located on vagal afferent neurons in the gastrointestinal tract as well as in the chemoreceptor trigger zone (CTZ), granisetron effectively suppresses serotonin-mediated activation of the vomiting reflex. Its high receptor specificity minimizes interaction with other neurotransmitter systems, including dopaminergic, histaminergic, and muscarinic pathways, thereby reducing off-target pharmacological effects and improving tolerability

compared to earlier antiemetic agents such as dopamine antagonists .[1,2,7,12] From a pharmacodynamic perspective, granisetron exhibits strong binding affinity and prolonged receptor occupancy at 5-HT3 receptor sites, contributing to sustained antiemetic efficacy even after plasma concentrations begin to decline . This selective receptor blockade ensures effective inhibition of ligand-gated ion channel activation associated with emetic signaling while minimizing central nervous system-related adverse effects such as sedation and extrapyramidal symptoms.[7,25] Pharmacokinetically, granisetron demonstrates consistent oral absorption with bioavailability ranging from approximately 50–60%, although it undergoes moderate first-pass hepatic metabolism. The drug is primarily metabolized in the liver via cytochrome P450 enzymes, particularly CYP3A isoforms, and its metabolites are eliminated through both renal and fecal pathways.[1]Granisetron exhibits an elimination half-life of approximately 6–9 hours, supporting sustained therapeutic activity and enabling effective control of both acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV) .Clinically, granisetron is administered in oral, intravenous, and transdermal formulations, with typical dosing regimens tailored according to the emetogenic potential of chemotherapy [. The availability of transdermal systems further enhances patient compliance by providing continuous drug delivery over extended periods, particularly in multi-day chemotherapy protocols .[12,8,18]Granisetron is commonly used as part of combination antiemetic therapy, especially in patients receiving highly emetogenic chemotherapy. The concomitant use of corticosteroids, such as dexamethasone, and neurokinin-1 (NK1) receptor antagonists significantly enhances therapeutic outcomes by targeting multiple emetic pathways simultaneously. This multimodal approach improves overall efficacy and reduces the incidence of breakthrough nausea and vomiting. Although granisetron has a relatively low potential for drug interactions, caution is advised when it is co-administered with agents that influence cytochrome P450 activity, particularly CYP3A inhibitors or inducers . Additionally, the concurrent use of other serotonergic agents may theoretically increase the risk of serotonin-related adverse effects, although such occurrences remain uncommon in clinical practice.[2,7,10]

Dosing routes:

Granisetron is available via multiple administration routes, including oral, intravenous, transdermal, and subcutaneous systems, offering flexibility in the management of chemotherapy-induced nausea and vomiting (CINV). Oral granisetron is generally administered within 1 hour prior to chemotherapy at a dose of 1–2 mg/day in adults, while pediatric dosing ranges between 20–40 µg/kg per dose .Intravenous administration is commonly employed in acute settings, with recommended doses of 1 mg or 10 µg/kg in adults and up to 40 µg/kg in pediatric patients .[1,29] The transdermal granisetron system delivers approximately 3.1 mg/day and should be applied 24–48 hours before chemotherapy, providing sustained antiemetic effects for up to 7 days.[4] Additionally, extended-release subcutaneous formulations (10 mg) administered prior to chemotherapy have demonstrated prolonged therapeutic plasma concentrations, ensuring extended control of CINV. These diverse delivery approaches improve therapeutic outcomes and patient adherence across different clinical scenarios.[5]

Phase II Clinical Trials

Initial phase II clinical investigations performed during the late 1980s confirmed the effectiveness and safety of Granisetron for the prevention of chemotherapy-induced nausea and vomiting (CINV). Various dosage regimens ranging from 2 to 160 µg/kg were assessed, with doses between 10 and 40 µg/kg demonstrating the best balance between efficacy and tolerability. In patients receiving highly emetogenic chemotherapy (HEC), complete control of emesis was achieved in approximately 63–70% of cases, whereas only 3–5% of patients experienced treatment failure. These studies highlighted the significant role of granisetron in the management of acute CINV and supported its further clinical development as an effective antiemetic agent.[30,31]

Phase III Clinical Trials

Phase III clinical studies demonstrated that Granisetron showed antiemetic efficacy comparable to conventional therapies such as high-dose Metoclopramide combined with Dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV). Granisetron exhibited improved tolerability with significantly fewer extrapyramidal adverse effects compared with traditional antiemetic regimens. Comparative studies also indicated similar efficacy between granisetron and other first-generation 5-HT3 antagonists including Ondansetron and Tropisetron. However, granisetron demonstrated limited activity in delayed CINV, leading to the use of combination therapy with dexamethasone for improved antiemetic control. Later studies comparing granisetron with Palonosetron suggested better delayed CINV prevention with palonosetron-based regimens, although

overall findings remained inconsistent.[32,33] Recent phase III studies have focused on novel delivery systems of Granisetron, including transdermal and extended-release formulations, to improve antiemetic efficacy and patient compliance. The granisetron transdermal delivery system (GDS) showed efficacy comparable to oral granisetron in preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV). Similarly, extended-release subcutaneous formulations such as AFP530 demonstrated prolonged antiemetic activity and improved delayed CINV control, particularly when combined with Dexamethasone and neurokinin-1 receptor antagonists.[34]

Post-Marketing Surveillance

Post-marketing surveillance studies demonstrated that the Granisetron transdermal patch showed antiemetic efficacy comparable to intravenous Palonosetron in the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy. Furthermore, crossover studies indicated greater patient satisfaction and convenience with the transdermal formulation, highlighting its potential to improve treatment adherence and patient quality of life due to its non-invasive mode of administration.[34]

Innovations in Drug Delivery Systems

Recent advancements in pharmaceutical technology have led to the development of innovative drug delivery systems aimed at overcoming the limitations associated with conventional formulations of granisetron. These novel approaches focus on enhancing bioavailability, improving patient compliance, and ensuring sustained therapeutic action in the management of chemotherapy-induced nausea and vomiting (CINV) [17,18].

- **Transdermal Drug Delivery Systems**

Transdermal delivery systems represent a significant advancement in the administration of granisetron, enabling continuous and controlled release of the drug across the skin into systemic circulation These systems maintain relatively stable plasma drug concentrations over extended periods, often up to several days, thereby providing prolonged antiemetic coverage during chemotherapy cycles

The avoidance of gastrointestinal absorption and hepatic first-pass metabolism further enhances the bioavailability of the drug, while reducing interpatient variability. Additionally, transdermal patches improve patient adherence by minimizing the need for frequent dosing and offering a non-invasive, convenient mode of administration However, factors such as skin permeability and potential local irritation may influence drug absorption and therapeutic performance[18-20]

- **Buccal Drug Delivery Systems**

Buccal drug delivery systems have gained considerable attention due to their ability to deliver drugs directly through the oral mucosa into systemic circulation In the case of granisetron, buccal formulations such as mucoadhesive tablets and films bypass hepatic first-pass metabolism, resulting in improved bioavailability and rapid onset of action

These systems are particularly advantageous for patients experiencing severe nausea or difficulty in swallowing conventional dosage forms, as they allow drug administration without the need for water . Furthermore, the use of mucoadhesive polymers enhances residence time at the site of absorption, facilitating sustained drug release and improved therapeutic efficacy.[21,22]

- **Fast Dissolving Oral Systems**

Fast dissolving oral dosage forms, including orally disintegrating tablets (ODTs) and oral films, offer a patient-friendly alternative for granisetron delivery. These formulations rapidly disintegrate in saliva within seconds, enabling quick drug release and absorption without the need for swallowing intact tablets. Such systems are particularly beneficial during acute episodes of nausea and vomiting, where conventional oral administration may be impractical. In addition to improving patient convenience, fast dissolving systems enhance compliance, especially in pediatric, geriatric, and oncology patients who may have difficulty swallowing .[23,24]

- **Nanocarrier-Based Drug Delivery Systems**

Nanotechnology-based drug delivery systems have emerged as a promising strategy for improving the therapeutic performance of granisetron. Various nanocarriers, including polymeric nanoparticles, liposomes, and solid lipid nanoparticles, have been investigated for their ability to enhance drug solubility, stability, and controlled release. These systems provide several advantages, such as protection of the drug from degradation, improved pharmacokinetic profiles, and the potential for targeted delivery to specific tissues. Controlled and sustained drug release from nanocarriers can reduce dosing frequency and minimize systemic side effects, thereby improving overall treatment outcome.

Furthermore, nanotechnology-based approaches align with modern pharmaceutical development strategies, including Quality by Design (QbD), ensuring optimized formulation performance and reproducibility.[17,25,26]

Table 1: Comparison of Granisetron Drug Delivery Systems [1-12]

Drug Delivery System	Route	Mechanism of Drug Release	Advantages	Limitations
Oral Tablets	Oral	Immediate release via gastrointestinal absorption	Easy administration, widely available	First-pass metabolism; reduced absorption during vomiting
Injectable (IV)	Intravenous	Direct systemic delivery	Complete bioavailability; rapid onset of action	Requires trained personnel; invasive
Transdermal Patch	Transdermal	Controlled diffusion across skin layers	Sustained release; improved patient compliance; avoids first-pass metabolism	Skin irritation; variability in absorption
Buccal Systems	Buccal mucosa	Mucoadhesive absorption through oral mucosa	Bypasses hepatic metabolism; rapid onset	Limited drug loading; taste-related issues
Fast Dissolving Tablets/Films	Oral (rapid dissolve)	Rapid disintegration in saliva followed by absorption	No need for water; convenient during nausea	Moisture sensitivity; stability concerns
Nanocarrier Systems	Systemic Targeted	Controlled and targeted drug release	Improved solubility; reduced toxicity; sustained effect	Complex formulation; higher cost

Table 2: Advanced Drug Delivery Systems – Functional Comparison

Parameter	Transdermal	Buccal	Fast Dissolving	Nanocarriers
Bioavailability	High	High	Moderate–High	Very High
First-pass metabolism	Avoided	Avoided	Partial	Avoided
Onset of Action	Slow–Moderate	Rapid	Very Rapid	Controlled
Duration of Action	Long (days)	Moderate	Short	Long
Patient Compliance	Excellent	Good	Excellent	Moderate
Suitability in Vomiting	Excellent	Excellent	Excellent	Excellent
Formulation Complexity	Moderate	Moderate	Low	High

Clinical Effectiveness and Safety

Granisetron has consistently demonstrated significant clinical efficacy in the prevention and management of chemotherapy-induced nausea and vomiting (CINV) across a wide range of emetogenic chemotherapy regimens. As a selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist, it effectively inhibits serotonin-mediated signaling pathways involved in the initiation of the emetic reflex, thereby providing reliable control of acute symptoms. Clinical studies have reported that granisetron is particularly effective in the acute phase of CINV, with sustained benefits observed when used in optimized dosing regimens. The safety profile of granisetron is well established, with most adverse effects being mild, transient, and generally well tolerated by patients. Commonly reported side effects include headache, constipation, and occasional gastrointestinal disturbances, which rarely necessitate discontinuation of therapy. Unlike earlier antiemetic agents, granisetron exhibits minimal sedation and a low incidence of extrapyramidal symptoms, contributing to improved patient acceptability.

Despite its efficacy as monotherapy, current clinical guidelines recommend the use of granisetron as part of combination antiemetic regimens, particularly in patients receiving highly emetogenic chemotherapy. The addition of corticosteroids, such as dexamethasone, and neurokinin-1 (NK1) receptor antagonists has been shown to enhance therapeutic outcomes by targeting multiple emetic pathways simultaneously. This multimodal approach significantly improves control over both acute and delayed phases of CINV, thereby optimizing patient quality of life and adherence to chemotherapy protocols.[1-10]

Table No:3 Clinical Profile of Granisetron in CINV Management

Parameter	Description	Clinical Significance
Drug Class	5-HT3 receptor antagonist	Blocks serotonin-mediated emesi
Primary Use	Prevention of CINV	Effective in acute phase
Onset of Action	Rapid (within 1–2 hours)	Quick symptom relief
Duration of Action	Moderate to long	Covers chemotherapy cycle
Common Adverse Effects	Headache, constipation, mild GI disturbances	Generally well tolerated
Serious Adverse Effects	Rare	Safe compared to older antiemeti
Combination Therapy	With corticosteroids & NK1 antagonists	Improved efficacy in delayed CIN
Patient Compliance	High	Better tolerability and convenienc



Fig. no.1: Mechanism of Action and Combination Therapy of Granisetron in Chemotherapy-Induced Nausea and Vomiting

Future Directions

Future advancements in the management of chemotherapy-induced nausea and vomiting (CINV) are expected to focus on the development of personalized antiemetic strategies tailored to individual patient characteristics, including genetic profile, type of malignancy, and specific chemotherapy regimens[2,25]. Variability in patient response to antiemetic therapy highlights the need for precision medicine approaches that optimize drug selection and dosing to achieve improved therapeutic outcomes Emerging research is increasingly exploring the integration of pharmacogenomics to better understand interindividual differences in drug metabolism and receptor sensitivity, which may significantly influence the efficacy of granisetron and other antiemetic agents .[2,10] Such approaches have the potential to minimize adverse effects while maximizing clinical benefit, thereby enhancing overall patient care in oncology settings.

In parallel, the application of advanced drug delivery technologies, particularly nanomedicine, is anticipated to play a pivotal role in the future of antiemetic therapy . Nanocarrier-based systems offer improved drug solubility, protection from degradation, and controlled

release profiles, which can enhance the pharmacokinetic and pharmacodynamic performance of granisetron . Additionally, these systems may enable targeted delivery to specific tissues, reducing systemic exposure and associated side effects [17,21]

The incorporation of Quality by Design (QbD) principles into formulation development further supports the creation of robust, reproducible, and high-quality drug delivery systems [7]. By systematically identifying critical formulation and process parameters, QbD facilitates optimization of product performance and ensures regulatory compliance [14,8]

Furthermore, future research should emphasize the development of patient-friendly dosage forms, such as transdermal systems, buccal films, and fast dissolving formulations, which improve adherence and convenience, particularly in outpatient settings [21]. The integration of digital health technologies and real-time monitoring tools may also enhance treatment outcomes by enabling better assessment of patient response and timely therapeutic adjustments .Overall, the convergence of personalized medicine, advanced drug delivery systems, and regulatory-driven design approaches is expected to significantly improve the effectiveness and safety of antiemetic therapy in the coming years [2,16].

Table: Emerging Strategies and Future Directions in CINV Management[2,16,21,10]

Strategy	Description	Future Impact
Personalized Medicine	Tailoring antiemetic therapy based on patient-specific factors such as genetics and chemotherapy regimen	Improved therapeutic efficacy reduced adverse effects
Pharmacogenomics	Study of genetic variations affecting drug response and metabolism	Optimized dosing and minin interpatient variability
Nanotechnology-Based Delivery	Use of nanoparticles for targeted and controlled drug delivery	Enhanced bioavailability and red systemic toxicity
Quality by Design (QbD)	Systematic approach to formulation development based on risk assessment and process optimization	Improved product qu consistency, and regul compliance
Novel Drug Delivery Systems	Development of transdermal, buccal, and fast dissolving formulations	Increased patient compliance convenience
Digital Health Integration	Use of monitoring tools and AI-based systems for treatment optimization	Better patient monitoring personalized treatment adjustmen

Conclusion

Granisetron remains a cornerstone in the prevention and management of chemotherapy-induced nausea and vomiting (CINV), owing to its well-established efficacy, favorable safety profile, and selective antagonism of 5-hydroxytryptamine type 3 (5-HT3) receptors. Its clinical utility has been consistently demonstrated across a wide spectrum of chemotherapy regimens, particularly in controlling acute emetic episodes and improving patient quality of life. Despite these advantages, limitations associated with conventional dosage forms have highlighted the need for innovative drug delivery approache . In this context, recent advancements in pharmaceutical technologies, including transdermal systems, buccal formulations, fast dissolving dosage forms, and nanocarrier-based delivery systems, have significantly enhanced the therapeutic performance of granisetron. These novel systems offer improved bioavailability, sustained drug release, reduced dosing frequency, and better patient compliance, which are critical factors in oncology care. Furthermore, the integration of combination antiemetic therapy, targeting multiple emetic pathways, has further strengthened the clinical effectiveness of granisetron in both acute and delayed phases of CINV. The incorporation of emerging strategies such as personalized medicine, pharmacogenomics, and Quality by Design (QbD) principles is expected to optimize treatment outcomes and ensure consistent product quality.

In conclusion, continued innovation in formulation design, coupled with a deeper understanding of CINV pathophysiology and patient-specific factors, is essential to achieve optimal therapeutic control. Future research should focus on developing patient-centric, targeted, and technologically advanced delivery systems that can further enhance the efficacy and safety of granisetron in cancer supportive care.

References

1. Hesketh PJ. Chemotherapy-induced nausea and vomiting. New England Journal of Medicine. 2008 Jun 5;358(23):2482-94.
2. Navari RM. Nausea and vomiting in advanced cancer. Current treatment options in oncology. 2020 Feb;21(2):14.
3. Roila F, Warr D, Hesketh PJ, Gralla R, Herrstedt J, Jordan K, Aapro M, Ballatori E, Rapoport B. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following moderately emetogenic chemotherapy. Supportive Care in Cancer. 2017 Jan;25(1):289-94.
4. Saito T, Tabata T, Ikushima H, Yanai H, Tashiro H, Niikura H, Minaguchi T, Muramatsu T, Baba T, Yamagami W, Ariyoshi K. Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer. International Journal of Clinical Oncology. 2018 Apr;23(2):201-34.
5. Saito R, Takano Y, Kamiya HO. Roles of substance P and NK1 receptor in the brainstem in the development of emesis. Journal of pharmacological sciences. 2003;91(2):87-94.

6. Gralla RJ. Anti-emesis with cancer chemotherapy. European Journal of Cancer. 1997 May 1;33:S63-7.
7. Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology. 2017 Oct 1;35(28):3240-61.
8. Aapro MS. Palonosetron as an anti-emetic and anti-nausea agent in oncology. Therapeutics and clinical risk management. 2007 Dec 30;3(6):1009-20.
9. Doggrell SA. Granisetron in the treatment of chemotherapy-induced nausea and vomiting (CINV)–is there still a role after comparison with palonosetron?. Expert Opinion on Pharmacotherapy. 2017 Jul 3;18(10):1019-26.
10. Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Annals of Oncology. 2015 Jun 1;26(6):1081-90.
11. Tuca A. Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review. Cancer management and research. 2010 Dec 16:1-2.
12. Deeks ED. Granisetron extended-release injection: a review in chemotherapy-induced nausea and vomiting. Drugs. 2016 Dec;76(18):1779-86.
13. Patel DJ, Patel JK. Design and evaluation of famotidine mucoadhesive nanoparticles for aspirin induced ulcer treatment. Brazilian Archives of Biology and Technology. 2013;56:223-36.
14. Vya AJ, Visana NM, Patel AI, Patel AB, Patel NK, Shah SR. Analytical quality by design in stress testing or stability-indicating method. Asian Journal of Pharmaceutical Analysis. 2021 Jun 1;11(2).
15. El-Say KM, Ahmed TA. Buccal route of drug delivery. InThe ADME Encyclopedia: A Comprehensive Guide on Biopharmacy and Pharmacokinetics 2022 Jun 15 (pp. 222-231). Cham: Springer International Publishing.
16. Rapoport BL, Herrstedt J, Snow RC, Radhakrishnan V, Saito M, Navari RM, Smit T. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Supportive Care in Cancer. 2024 Jan;32(1):36.
17. Patel ZS, Yamamoto M, Ueda H, Tabata Y, Mikos AG. Biodegradable gelatin microparticles as delivery systems for the controlled release of bone morphogenetic protein-2. Acta biomaterialia. 2008 Sep 1;4(5):1126-38.
18. Yang YL, Liu L, Wang Y, Wu H, Yang XS, Wang JN, Wang L. The prevalence of depression and anxiety among Chinese adults with cancer: a systematic review and meta-analysis. BMC cancer. 2013 Aug 22;13(1):393.
19. Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Annals of Oncology. 2007 Feb 1;18(2):233-40.
20. Yahata H, Kobayashi H, Sonoda K, Shimokawa M, Ohgami T, Saito T, Ogawa S, Sakai K, Ichinoe A, Ueoka Y, Hasuo Y. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. International journal of clinical oncology. 2016 Jun;21(3):491-7.
21. Ito C, Isobe Y, Kawamura R, Kiuchi Y, Tsuchida K, Higuchi S. Effect of GK-128 [2-[(2-methylimidazol-1-yl) methyl] benzo [f] thiochromen-1-one monohydrochloride hemihydrate], a selective 5-hydroxytryptamine3 receptor antagonist, on colonic function in rats. The Journal of pharmacology and experimental therapeutics. 1997 Jan 1;280(1):67-72.
22. Shinde RB, Asokan BR, Kunam V, Waris H, Khatoon Y, Pattewar SV, Ansari S, Shahare SH. development and evaluation of granisetron transdermal patches for supportive therapy of chemotherapy induced nausea and vomiting. Bulletin of Pure & Applied Sciences-Zoology. 2024 Jul 2;43.
23. Rojas C, Slusher BS. Pharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-

induced nausea and vomiting. European journal of pharmacology. 2012 Jun 5;684(1-3):1-7.

24. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. The journal of supportive oncology. 2011 Oct 31;9(5):188-95.
25. International Council for Harmonisation. ICH Q8 (R2): Pharmaceutical Development. 2009.
26. International Council for Harmonisation. ICH Q9: Quality Risk Management. 2005.
27. Jordan K, Gralla R, Jahn F, Molassiotis A. Antiemetics: MASCC/ESMO clinical practice guidelines for antiemetic therapy
28. Joss RA, Dott CS, Granisetron Study Group. Clinical studies with granisetron, a new 5-HT3 receptor antagonist for the treatment of cancer chemotherapy-induced emesis. European Journal of Cancer. 1993 Jan 1;29:S22-9.
29. Chevallier BO. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group. European Journal of Cancer (Oxford, England: 1990). 1990 Jan 1;26:S33-6.
30. Einhorn LH, Nagy C, Werner K, Finn AL. Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy. Journal of Clinical Oncology. 1990 Apr;8(4):731-5.
31. Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. The lancet oncology. 2009 Feb 1;10(2):115-24.
32. Boccia RV, Gordan LN, Clark G, Howell JD, Grunberg SM, Sancuso Study Group. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Supportive Care in Cancer. 2011 Oct;19(10):160917.